Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: Implications for immunotherapy

Cancer Immunology, Immunotherapy

Volumn 61, Issue 7, 2012, Pages 1005-1018

  Castro, Fernanda V ^a   Al Muftah, Mariam ^a,d   Mulryan, Kate ^a   Jiang, Hui Rong ^a,b   Drijfhout, Jan Wouter ^c   Ali, Sumia ^a   Rutkowski, Andrzej J ^a   Kalaitsidou, Milena ^a   Gilham, David E ^d   Stern, Peter L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

5T4 oncofoetal antigen; Immunotherapy; T cell epitopes; T cell repertoire; T regulatory cells; Vaccine

Indexed keywords

CANCER VACCINE; EPITOPE; FOLATE RECEPTOR; FOLATE RECEPTOR 4; FOLIC ACID ANTAGONIST; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; ONCOFETAL ANTIGEN; ONCOFETAL ANTIGEN 5T4; REPLICATION DEFECTIVE ADENOVIRUS ENCODING MOUSE 5T4 VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOLOGOUS IMMUNITY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL LOSS; CELL PROTECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HOMEOSTASIS; IMMUNITY; IMMUNOGENICITY; IMMUNOREGULATION; IN VIVO STUDY; KNOCKOUT MOUSE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROVOCATION TEST; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; IMMUNOTHERAPY, ACTIVE; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES, REGULATORY;

EID: 84862773091     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1167-3     Document Type: Article

References (51)

1. SA Rosenberg JC Yang NP Restifo 2004 Cancer immunotherapy: moving beyond current vaccines Nat Med 10 9 909 915 10.1038/nm1100 15340416 10.1038/nm1100 1:CAS:528:DC%2BD2cXntFSktL0%3D
2. M Dougan G Dranoff 2009 Immune therapy for cancer Annu Rev Immunol 27 83 117 10.1146/annurev.immunol.021908.132544 19007331 10.1146/annurev.immunol. 021908.132544 1:CAS:528:DC%2BD1MXlsFSlsbo%3D
3. N Hole PL Stern 1988 A 72 kD trophoblast glycoprotein defined by a monoclonal antibody Br J Cancer 57 3 239 246 3355761 10.1038/bjc.1988.53 1:CAS:528:DyaL1cXitVarsbc%3D
4. N Hole PL Stern 1990 Isolation and characterization of 5T4, a tumour-associated antigen Int J Cancer 45 1 179 184 2298503 10.1002/ijc. 2910450132 1:STN:280:DyaK3c7ivFCiug%3D%3D
5. PJ Southall GM Boxer KD Bagshawe N Hole M Bromley PL Stern 1990 Immunohistological distribution of 5T4 antigen in normal and malignant tissues Br J Cancer 61 1 89 95 2404511 10.1038/bjc.1990.20 1:STN:280: DyaK3c7it1GrtQ%3D%3D
6. H Naganuma K Kono Y Mori S Takayoshi PL Stern K Tasaka Y Matsumoto 2002 Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer Anticancer Res 22 2B 1033 1038 12168897 1:CAS:528:DC%2BD38XmsFWrsr4%3D
7. T Starzynska PJ Marsh PF Schofield SA Roberts KA Myers PL Stern 1994 Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma Br J Cancer 69 5 899 902 8180020 10.1038/bjc.1994.173 1:STN:280:DyaK2c3jsFCntg%3D%3D
8. E Wrigley AT McGown J Rennison R Swindell D Crowther T Starzynska PL Stern 1995 5T4 oncofetal antigen expression in ovarian carcinoma Int J Gynecol Cancer 5 4 269 274 05040269 11578488 10.1046/j.1525-1438.1995.05040269.x
9. A Awan MR Lucic DM Shaw F Sheppard C Westwater SA Lyons PL Stern 2002 5T4 interacts with TIP-2/GIPC, a PDZ protein, with implications for metastasis Biochem Biophys Res Commun 290 3 1030 1036 10.1006/bbrc.2001.6288 11798178 10.1006/bbrc.2001.6288 1:CAS:528:DC%2BD38XksVyqsw%3D%3D
10. CJ Carsberg KA Myers PL Stern 1996 Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells Int J Cancer 68 1 84 92 10.1002/(SICI)1097-0215(19960927)68:1<84::AID- IJC15>3.0.CO;2-6 8895545 10.1002/(SICI)1097-0215(19960927)68:1<84::AID- IJC15>3.0.CO;2-6 1:CAS:528:DyaK28XmsFyhurc%3D
11. TD Southgate OJ McGinn FV Castro AJ Rutkowski M Al-Muftah G Marinov GJ Smethurst D Shaw CM Ward CJ Miller PL Stern 2010 CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells PLoS One 5 4 9982 10.1371/journal.pone.0009982 10.1371/journal.pone.0009982
12. DM Shaw NB Connolly PM Patel S Kilany G Hedlund O Nordle G Forsberg J Zweit PL Stern RE Hawkins 2007 A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma Br J Cancer 96 4 567 574 10.1038/sj.bjc.6603567 17285137 10.1038/sj.bjc.6603567 1:CAS:528:DC%2BD2sXhvV2jsbY%3D
13. ER Boghaert L Sridharan KM Khandke D Armellino MG Ryan K Myers R Harrop A Kunz PR Hamann K Marquette M Dougher JF DiJoseph NK Damle 2008 The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin Int J Oncol 32 1 221 234 18097562 1:CAS:528: DC%2BD1cXhtVOlu7s%3D
14. RW Griffiths DE Gilham A Dangoor V Ramani NW Clarke PL Stern RE Hawkins 2005 Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy Br J Cancer 93 6 670 677 10.1038/sj.bjc.6602776 16222313 10.1038/sj.bjc.6602776 1:CAS:528: DC%2BD2MXhtV2kt7rE
15. RD Guest RE Hawkins N Kirillova EJ Cheadle J Arnold A O'Neill J Irlam KA Chester JT Kemshead DM Shaw MJ Embleton PL Stern DE Gilham 2005 The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens J Immunother 28 3 203 211 00002371-200505000-00005 15838376 10.1097/01.cji.0000161397.96582.59 1:CAS:528:DC%2BD2MXjtlKlurc%3D
16. R Harrop W Shingler M Kelleher J de Belin P Treasure 2010 Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients J Immunother 33 9 999 1005 10.1097/CJI.0b013e3181f5dac7 20948436 10.1097/CJI.0b013e3181f5dac7 1:CAS:528:DC%2BC3cXhtlGkurbE
17. RJ Amato RE Hawkins HL Kaufman JA Thompson P Tomczak C Szczylik M McDonald S Eastty WH Shingler J de Belin M Goonewardena S Naylor R Harrop 2010 Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study Clin Cancer Res 16 22 5539 5547 10.1158/1078-0432.CCR-10-2082 20881001 10.1158/1078-0432.CCR-10-2082 1:CAS:528:DC%2BC3cXhsVWmsbnN
18. R Harrop WH Shingler M McDonald P Treasure RJ Amato RE Hawkins HL Kaufman J de Belin M Kelleher M Goonewardena S Naylor 2011 MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients Cancer Immunol Immunother 60 6 829 837 10.1007/s00262-011-0993-7 21387109 10.1007/s00262-011-0993-7 1:CAS:528:DC%2BC3MXmsVajtLw%3D
19. K Mulryan MG Ryan KA Myers D Shaw W Wang SM Kingsman PL Stern MW Carroll 2002 Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors Mol Cancer Ther 1 12 1129 1137 12481437 1:CAS:528:DC%2BD3sXmtFamtw%3D%3D
20. JW Greiner H Zeytin MR Anver J Schlom 2002 Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity Cancer Res 62 23 6944 6951 12460911 1:CAS:528:DC%2BD38XpsVahsLk%3D
21. JW Hodge DW Grosenbach WM Aarts DJ Poole J Schlom 2003 Vaccine therapy of established tumors in the absence of autoimmunity Clin Cancer Res 9 5 1837 1849 12738742 1:CAS:528:DC%2BD3sXjsFeitLs%3D
22. M Kmieciak JK Morales J Morales E Bolesta M Grimes MH Manjili 2008 Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design Cancer Immunol Immunother 57 9 1391 1398 10.1007/s00262-008-0475-8 18278493 10.1007/s00262-008-0475-8 1:CAS:528:DC%2BD1cXnsFeis7s%3D
23. GY Song G Gibson W Haq EC Huang T Srivasta M Hollstein P Daftarian Z Wang D Diamond JD Ellenhorn 2007 An MVA vaccine overcomes tolerance to human p53 in mice and humans Cancer Immunol Immunother 56 8 1193 1205 10.1007/s00262-006- 0270-3 17219151 10.1007/s00262-006-0270-3 1:CAS:528:DC%2BD2sXltlSkt7s%3D
24. H Ishizaki ER Manuel GY Song T Srivastava S Sun DJ Diamond JD Ellenhorn 2011 Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model Cancer Immunol Immunother 60 1 99 109 10.1007/s00262-010-0923-0 20960189 10.1007/s00262-010-0923-0 1:CAS:528:DC%2BC3MXht12gtrs%3D
25. WW Overwijk MR Theoret SE Finkelstein DR Surman LA de Jong FA Vyth-Dreese TA Dellemijn PA Antony PJ Spiess DC Palmer DM Heimann CA Klebanoff Z Yu LN Hwang L Feigenbaum AM Kruisbeek SA Rosenberg NP Restifo 2003 Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells J Exp Med 198 4 569 580 10.1084/jem.20030590 12925674 10.1084/jem.20030590 1:CAS:528:DC%2BD3sXms1WisL4%3D
26. A Saha SK Chatterjee KA Foon E Celis M Bhattacharya-Chatterjee 2007 Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen Cancer Res 67 6 2881 2892 10.1158/0008-5472.CAN-06-3045 17363612 10.1158/0008-5472.CAN-06-3045 1:CAS:528:DC%2BD2sXivV2ntr4%3D
27. A Kimura T Kishimoto 2010 IL-6: regulator of Treg/Th17 balance Eur J Immunol 40 7 1830 1835 20583029 10.1002/eji.201040391 1:CAS:528: DC%2BC3cXotVOkurc%3D
28. MW Teng JB Swann B von Scheidt J Sharkey N Zerafa N McLaughlin T Yamaguchi S Sakaguchi PK Darcy MJ Smyth 2010 Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion Cancer Res 70 7 2665 2674 20332236 10.1158/0008-5472.CAN-09-1574 1:CAS:528:DC%2BC3cXktFynsbo%3D
29. T Yamaguchi K Hirota K Nagahama K Ohkawa T Takahashi T Nomura S Sakaguchi 2007 Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor Immunity 27 1 145 159 17613255 10.1016/j.immuni.2007.04.017 1:CAS:528:DC%2BD2sXosFeqt74%3D
30. HL Spencer AM Eastham CL Merry TD Southgate F Perez-Campo F Soncin S Ritson R Kemler PL Stern CM Ward 2007 E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells Mol Biol Cell 18 8 2838 2851 17507657 10.1091/mbc.E06-09-0875 1:CAS:528:DC%2BD2sXovFalurw%3D
31. AM Woods WW Wang DM Shaw CM Ward MW Carroll BR Rees PL Stern 2002 Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer Biochem J 366 Pt 1 353 365 10.1042/BJ20020104 12003637 1:CAS:528:DC%2BD3sXptFOhtb0%3D
32. S Ali K Mulryan T Taher PL Stern 2007 Immunotherapy success in prophylaxis cannot predict therapy: prime-boost vaccination against the 5T4 oncofoetal antigen Cancer Immunol Immunother 56 2 165 180 10.1007/s00262-006- 0179-x 16758205 10.1007/s00262-006-0179-x 1:CAS:528:DC%2BD28Xht1Gnu7vJ
33. KM Barrow CM Ward J Rutter S Ali PL Stern 2005 Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epithelia Dev Dyn 233 4 1535 1545 15977177 10.1002/dvdy.20482 1:CAS:528:DC%2BD2MXnvVWrur4%3D
34. P Muranski A Boni PA Antony L Cassard KR Irvine A Kaiser CM Paulos DC Palmer CE Touloukian K Ptak L Gattinoni C Wrzesinski CS Hinrichs KW Kerstann L Feigenbaum CC Chan NP Restifo 2008 Tumor-specific Th17-polarized cells eradicate large established melanoma Blood 112 2 362 373 10.1182/blood-2007-11-120998 18354038 10.1182/blood-2007-11-120998 1:CAS:528:DC%2BD1cXos1Cit70%3D
35. WW Overwijk DS Lee DR Surman KR Irvine CE Touloukian CC Chan MW Carroll B Moss SA Rosenberg NP Restifo 1999 Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes Proc Natl Acad Sci U S A 96 6 2982 2987 10077623 10.1073/pnas.96.6.2982 1:CAS:528:DyaK1MXhvFyksb4%3D
36. AG Brandmaier WW Leitner SP Ha J Sidney NP Restifo CE Touloukian 2009 High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction J Immunother 32 7 677 688 10.1097/CJI.0b013e3181ab1824 19561540 10.1097/CJI.0b013e3181ab1824
37. H Nishikawa S Sakaguchi 2010 Regulatory T cells in tumor immunity Int J Cancer 127 4 759 767 20518016 1:CAS:528:DC%2BC3cXnvFKru7k%3D
38. DM Simons CC Picca S Oh OA Perng M Aitken J Erikson AJ Caton 2010 How specificity for self-peptides shapes the development and function of regulatory T cells J Leukoc Biol 88 6 1099 1107 20495071 10.1189/jlb.0310183 1:CAS:528:DC%2BC3cXhsFGgtLzK
39. PA Antony CA Piccirillo A Akpinarli SE Finkelstein PJ Speiss DR Surman DC Palmer CC Chan CA Klebanoff WW Overwijk SA Rosenberg NP Restifo 2005 CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells J Immunol 174 5 2591 2601 174/5/2591 15728465 1:CAS:528:DC%2BD2MXhsFeru7Y%3D
40. NN Hunder H Wallen J Cao DW Hendricks JZ Reilly R Rodmyre A Jungbluth S Gnjatic JA Thompson C Yee 2008 Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1 N Engl J Med 358 25 2698 2703 10.1056/ NEJMoa0800251 18565862 10.1056/NEJMoa0800251 1:CAS:528:DC%2BD1cXns1ajtrw%3D
41. R Kennedy E Celis 2008 Multiple roles for CD4+ T cells in anti-tumor immune responses Immunol Rev 222 129 144 10.1111/j.1600-065X.2008.00616.x 18363998 10.1111/j.1600-065X.2008.00616.x 1:CAS:528:DC%2BD1cXlsFejtrk%3D
42. MR Parkhurst JC Yang RC Langan ME Dudley DA Nathan SA Feldman JL Davis RA Morgan MJ Merino RM Sherry MS Hughes US Kammula GQ Phan RM Lim SA Wank NP Restifo PF Robbins CM Laurencot SA Rosenberg 2010 T Cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis Mol Ther 19 3 620 626 21157437 10.1038/mt.2010.272
43. R Bos S van Duikeren H Morreau K Franken TN Schumacher JB Haanen SH van der Burg CJ Melief R Offringa 2008 Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen Cancer Res 68 20 8446 8455 18922918 10.1158/0008-5472.CAN-08-1864 1:CAS:528:DC%2BD1cXht1CmsbrI
44. MD Sharma DY Hou B Baban PA Koni Y He PR Chandler BR Blazar AL Mellor DH Munn 2010 Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice Immunity 33 6 942 954 21145762 10.1016/j.immuni.2010.11.022 1:CAS:528:DC%2BC3cXhsFyisLvM
45. VA Pudney RL Metheringham B Gunn I Spendlove JM Ramage LG Durrant 2010 DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8+ T cells Eur J Immunol 40 3 899 910 10.1002/eji.200939857 20039301 10.1002/eji.200939857 1:CAS:528: DC%2BC3cXjtVWku70%3D
46. L Garcia-Hernandez Mde H Hamada JB Reome SK Misra MP Tighe RW Dutton 2010 Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice J Immunol 184 8 4215 4227 10.4049/jimmunol.0902995 20237297 10.4049/jimmunol.0902995
47. T Kondo H Takata F Matsuki M Takiguchi 2009 Cutting edge: phenotypic characterization and differentiation of human CD8+ T cells producing IL-17 J Immunol 182 4 1794 1798 10.4049/jimmunol.0801347 19201830 10.4049/jimmunol. 0801347 1:CAS:528:DC%2BD1MXhsFKktL4%3D
48. HR Yen TJ Harris S Wada JF Grosso D Getnet MV Goldberg KL Liang TC Bruno KJ Pyle SL Chan RA Anders CL Trimble AJ Adler TY Lin DM Pardoll CT Huang CG Drake 2009 Tc17 CD8 T cells: functional plasticity and subset diversity J Immunol 183 11 7161 7168 10.4049/jimmunol.0900368 19917680 10.4049/jimmunol. 0900368 1:CAS:528:DC%2BD1MXhsVehsbrE
49. DM Kuang C Peng Q Zhao Y Wu LY Zhu J Wang XY Yin L Li L Zheng 2010 Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients J Immunol 185 3 1544 1549 10.4049/jimmunol. 0904094 20581151 10.4049/jimmunol.0904094 1:CAS:528:DC%2BC3cXptV2jsb8%3D
50. KS Sfanos TC Bruno CH Maris L Xu CJ Thoburn AM DeMarzo AK Meeker WB Isaacs CG Drake 2008 Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing Clin Cancer Res 14 11 3254 3261 10.1158/1078-0432.CCR-07-5164 18519750 10.1158/1078-0432.CCR-07-5164 1:CAS:528:DC%2BD1cXmslygs70%3D
51. FC Thistlethwaite E Elkord RW Griffiths DJ Burt AM Shablak JD Campbell DE Gilham EB Austin PL Stern RE Hawkins 2008 Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma Cancer Immunol Immunother 57 5 623 634 10.1007/s00262-007-0400-6 17899077 10.1007/s00262-007-0400-6